LOS ANGELES, CALIFORNIA – 12/27/2018 (PRDistribution.com)
Leonhardt’s Launchpads, an innovation and startup accelerator focused on organ regeneration technologies, announced today two innovation showcases to take place on Tuesday January 8th in San Francisco at WeWork 995 Market St, San Francisco, CA 94103 – just 7 minutes walk from the JP Morgan Healthcare Conference.
The first showcase 2pm to 5pm will feature Second Heart Assist www.secondheartinc.com which is developing a wireless powered chronic pulsatile circulatory assist aortic stent pump.
The 2nd showcase 5pm to 8pm will highlight the full portfolio www.leonhardtventures.com of organ regeneration startups being developed in the accelerator based on precise bioelectric signaling sequence control of regenerative protein expressions (including SDF1 and PDGF for stem cell homing) and when needed for severe organ needs also a micro infusion pump re-filled regularly with a proprietary fifteen component organ regeneration composition comprised of stem cells, exosomes, amniotic fluid, PRF, micro RNA gel, selected growth factors, selected alkaloids, oxygenated nano particles, nutrient hydrogel, ECM matrix and organ specific matrix.
Leonhardt’s Launchpads filed more than 180 new USPTO patent claims in 2018 alone related to regeneration of organs with a combination of bioelectrics and biologics. The focus of this research is to develop products to help people keep their own organs by regenerating them in your own body rather than get an artificial implant or a transplant from another person.
13 of 30 portfolio products are at or are near clinical stage of development for 2019 mostly in OUS studies. The primary benchtop bioelectric stimulator used for many studies already has FDA 510K market clearance for improving blood circulation, accelerated healing and mild pain relief. Data is being gathered to support a broadening of labelling and indications of use.
Bioelectric protein expressions under testing and evaluation for various applications include: SDF1, IGF1, EGF, HGF, PDGF, VEGF, HIF1a, TNFa, eNOS, Follistatin, Tropoelastin, Klotho, GDF10, GDF11, Neurogenin 3, BMP9, 10, IL1,6,9,33, RANKL and OPG.
Areas of focus include:
1. Heart & Cardiovascular (8 startups).
2. Brain (1 startup).
3. Cosmetic & Personal Care (8 startups)
4. Major Organ Regeneration (12 startups).
5. Cancer (1 startup).
Innovation Showcase(s) Ticket information is below (limited space order now):
1. Second Heart Assist Innovation Showcase 2pm to 5pm – tickets here > https://www.eventbrite.com/e/second-heart-assist-innovation-showcase-wireless-powered-circulatory-assist-tickets-53840142315?utm-medium=discovery&utm-campaign=social&utm-content=attendeeshare&aff=escb&utm-source=cp&utm-term=listing
Second Heart Assist Innovation Showcase Deck 2 to 5pm Jan. 8th Slide Deck Here > https://app.slidebean.com/p/dzBAKzBo4r/SecondHeart30SlideDeck
2. Leonhardt’s Launchpads Organ Regeneration Innovation Showcase 5pm to 8pm – tickets here > https://www.eventbrite.com/e/organ-regeneration-innovation-showcase-leonhardts-launchpads-tickets-53838174429?utm-medium=discovery&utm-campaign=social&utm-content=attendeeshare&aff=escb&utm-source=cp&utm-term=listing
Organ Regeneration Innovation Showcase Deck 5pm to 8pm Jan. 8th Slide Deck Here > https://app.slidebean.com/p/AaDUz4CxmQ/Leonhardts-Launchpads-Short-Deck-2
Development Stage Pipeline Website Page Click Here > https://leonhardtventures.com/development-pipeline/
2018 Elevator Pitches for Startup by Startup Click Here > https://leonhardtventures.com/2018-elevator-pitches/
Innovation and startup accelerator FOCUSED on organ regeneration with a convergence of bioelectrics and biologics.
2019 Portfolio of Startups
HEART AND CARDIOVASCULAR
> BioLeonhardt – heart regeneration.
> AortaCell – aorta regeneration.
> BioPace – biological pacemaker regeneration.
> Valvublator – heart valve decalcification and regeneration.
> VibroCell CoroStim– vibrational energy to prevent clots, plaque, calcification.
> Vascustim (formerly MyoStim Peripheral)– limb blood flow improvement.
> Second Heart Assist, Inc. – circulatory assist pumps
> PressureStim – bioelectric blood pressure control.
> CerebraCell – brain regeneration.
Cosmetic & Personal Care
> Stem Cell Bra – breast regeneration.
> DentaCell Accelerator – dental gum regeneration + tooth pulp storage.
> OrthodontiCell – bioelectric teeth straightening acceleration.
> SkinStim (formerly MyoStim Skin) – skin regeneration.
> MyoStim ED ErectiStim – bioelectric erectile dysfunction treatment.
> HairCell – hair regeneration
> TestiStim – bioelectric testosterone management and infertility treatment.
> Peach – bioelectric vaginal rejuvenation.
Major Organ Regeneration
> EyeCell – eye regeneration.
> PancreaCell – pancreas regeneration.
> RegenaLung – lung regeneration.
> LiverCell – liver regeneration.
> KidneyCell – kidney regeneration.
> EarCell – ear hearing regeneration.
> BladderCell – bladder regeneration.
> InStim – bioelectric inflammation management.
> PolypStim – bioelectric polyp removal.
>. OrthoStim – bioelectric and biologics joint recovery.
> Wave – bioelectric endometriosis treatment.
> BioLeonhardt Whole Body Regeneration – Whole body regeneration.
> CancerCell – bioelectric cancer tumor treatment + regeneration.
About Leonhardt’s Launchpads: Innovation and startup accelerator focused on organ regeneration and recovery technologies. Labs and research offices in California, Utah, Pittsburgh and Australia. Business model is to accelerate each organ specific innovation and startup through first-in-man clinical trial results and then seek a strategic partner. www..leonhardtventures.com
Precautionary Statement and Warning: Early stage developments are not yet proven to be safe or effective. Patent claims filed may not be issued. Patents issued or licensed may not be maintained. Company does not have sufficient resources on hand to develop all products mentioned. Release may include forward looking statements which may differ in actual performance forward. Corrections and changes may be made to any items listed or contents found in any links without special notice. Any mention of the regenerative or recovery potential of products is in the context of “designed to” and “under early stage testing not yet proven safe or effective in statistically significant clinical studies”.